gentuximab / GeneScience - LARVOL DELTA

Gentuximab plus paclitaxel versus placebo plus paclitaxel in second-line advanced G/GEJ adenocarcinoma: A randomized, double-blind, phase III trial (ESMO 2026) - No abstract available

Clinical • Metastases • P3 data • Gastroesophageal Junction Adenocarcinoma • Oncology

A Study of Gentuximab + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction Cancer (clinicaltrials.gov) - P1/2 | N=76 | Completed | Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd. | Unknown status ➔ Completed

Trial completion • Esophageal Cancer • Gastric Cancer • Oncology • Solid Tumor

Gentuximab Combined With Paclitaxel Compared With Placebo Combined With Paclitaxel for Gastric Adenocarcinoma. (clinicaltrials.gov) - P3 | N=752 | Recruiting | Sponsor: GeneScience Pharmaceuticals Co., Ltd.

Metastases • New P3 trial • Esophageal Cancer • Gastric Adenocarcinoma • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Oncology • Solid Tumor